Heidegger, 1931-1939: Interpretations on the kínesis. towards a dynamics and aleteiological ontology

Esta investigación se centra en las interpretaciones heideggerianas sobre la Física y la Metafísica de Aristóteles en la década de 1930 y, particularmente, en las nociones de kínesis y dynamis. En el horizonte de la verdad del ser, Heidegger entiende la kínesis –que no es reductible a mera dynamis sino que es enérgeia atelés– como ‘el movimiento de llegada a la presencia’, Anwesung. Así se evidencia que la suya es una lectura aleteiológica alineada con su comprensión del Ereignis, esto es, de la identidad (copertenencia) de pensar y ser. Esta lectura abre la posibilidad de entender la suya como una “ontología dinámica y aleteiológica”.This research focuses on the Heideggerian interpretations of Aristotle's Physics and Metaphysics in the 1930s and specially on the notions of kinesis and dynamis. In the horizon of the truth of the being, Heidegger understands kínesis –which is not reducible to mere dynamis but it is enérgeia atelés– as ‘the movement of coming-into-presence, Anwesung. This shows that his is a aleteiological reading aligned with his understanding of Ereignis, that is, of the identity of thinking and being. This reading opens the possibility of understanding his as a “dynamic and aleteiological ontology

Handbook of Active Ageing and Quality of Life: From Concepts to Applications

La edición de este libro estuvo a cargo de Fermina Rojo-Pérez y Gloria Fernández-Mayoralas.El documento adjunto contiene la cubierta, portada e índice del libro.This handbook presents an overview of studies on the relationship of active ageing and quality of life. It addresses the new challenges of ageing from the paradigm of positive ageing (active, healthy and successful) for a better quality of life. It provides theoretical perspectives and empirical studies, including scientific knowledge as well as practical experiences about the good ageing and the quality of later life around the world, in order to respond to the challenges of an aged population. The handbook is structured in 4 sections covering theoretical and conceptual perspectives, social policy issues and research agenda, methods, measurement instrument-scales and evaluations, and lastly application studies including domains and geographical contexts.Peer reviewe

Ramón Rodriguez: La Transformación hermenéutica de la Fenomenología. Una interpretación de la obra temprana de Heidegger.

Sin resume

BERCIANO VILLALIBRE, Modesto: La revolución filosófica de Martin Heidegger.

Sin resume

BERCIANO VILLALIBRE, Modesto: La revolución filosófica de Martin Heidegger.

Sin resume

Ramón Rodriguez: La Transformación hermenéutica de la Fenomenología. Una interpretación de la obra temprana de Heidegger.

Sin resume

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).

Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized trial investigating whether extending adjuvant temozolomide for more than 6 cycles improved outcome. Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after 6 cycles of adjuvant temozolomide were centrally randomized to stop (control arm) or continue (experimental arm) temozolomide up to a total of 12 cycles at the same doses they were receiving in cycle 6. Patients were stratified by MGMT methylation and measurable disease. The primary endpoint was differences in 6-month progression-free survival (PFS). Secondary endpoints were PFS, overall survival (OS), and safety (Clinicaltrials.gov NCT02209948). From August 2014 to November 2018, 166 patients were screened, 7 of whom were ineligible. Seventy-nine patients were included in the stop arm and 80 in the experimental arm. All patients were included in the analyses of outcomes and of safety. There were no differences in 6-month PFS (control 55.7%; experimental 61.3%), PFS, or OS between arms. MGMT methylation and absence of measurable disease were independent factors of better outcome. Patients in the experimental arm had more lymphopenia (P  Continuing temozolomide after 6 adjuvant cycles is associated with greater toxicity but confers no additional benefit in 6-month PFS. 1. Extending adjuvant temozolomide to 12 cycles did not improve 6-month PFS.2. Extending adjuvant temozolomide did not improve PFS or OS in any patient subset.3. Extending adjuvant temozolomide was linked to increased toxicities